These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 31087108)

  • 1. [Oral anticoagulation and antiplatelet therapy in patients with atrial fibrillation after coronary interventions].
    Schäfer A; Bauersachs J
    Herz; 2019 Jun; 44(4):365-378. PubMed ID: 31087108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Antithrombotic treatment in acute coronary syndrome and atrial fibrillation].
    Darius H; Görge G; Spiecker M; Schinzel H
    Herz; 2019 Feb; 44(1):29-34. PubMed ID: 30689009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of early clinical outcomes between dual antiplatelet therapy and triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention.
    Park J; Jung JH; Choi EK; Lee SW; Kwon S; Lee SR; Kang J; Han KD; Park KW; Oh S; Lip GYH
    PLoS One; 2022; 17(2):e0264538. PubMed ID: 35213632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of oral anticoagulants in combination with antiplatelet(s) in atrial fibrillation.
    Sindet-Pedersen C; Staerk L; Lamberts M; Gerds TA; Berger JS; Nissen Bonde A; Langtved Pallisgaard J; Hansen ML; Torp-Pedersen C; Gislason GH; Bjerring Olesen J
    Heart; 2018 Jun; 104(11):912-920. PubMed ID: 29092916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combining Oral Anticoagulants With Platelet Inhibitors in Patients With Atrial Fibrillation and Coronary Disease.
    Sindet-Pedersen C; Lamberts M; Staerk L; Nissen Bonde A; Berger JS; Pallisgaard JL; Lock Hansen M; Torp-Pedersen C; Gislason GH; Olesen JB
    J Am Coll Cardiol; 2018 Oct; 72(15):1790-1800. PubMed ID: 30286922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention: should we change our practice after the PIONEER AF-PCI and RE-DUAL PCI trials?
    Duerschmied D; Brachmann J; Darius H; Frey N; Katus HA; Rottbauer W; Schäfer A; Thiele H; Bode C; Zeymer U
    Clin Res Cardiol; 2018 Jul; 107(7):533-538. PubMed ID: 29679144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The optimal management of patients on oral anticoagulation undergoing coronary artery stenting. The 10th Anniversary Overview.
    Rubboli A; Faxon DP; Juhani Airaksinen KE; Schlitt A; Marín F; Bhatt DL; Lip GY
    Thromb Haemost; 2014 Dec; 112(6):1080-7. PubMed ID: 25298351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Update ESC-Guideline 2017: Dual Antiplatelet Therapy].
    Massberg S; Polzin A
    Dtsch Med Wochenschr; 2018 Aug; 143(15):1090-1093. PubMed ID: 30060279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concomitant Use of Antiplatelets and Anticoagulants in Patients with Coronary Heart Disease and Atrial Fibrillation: What Do Recent Clinical Trials Teach Us?
    Lam DH; Bell SM; Hira RS
    Curr Atheroscler Rep; 2018 Jan; 20(1):4. PubMed ID: 29349596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-Vitamin K Oral Anticoagulants (NOAC) Versus Vitamin K Antagonists (VKA) for Atrial Fibrillation with Elective or Urgent Percutaneous Coronary Intervention: A Meta-Analysis with a Particular Focus on Combination Type.
    Eyileten C; Postula M; Jakubik D; Toma A; Mirowska-Guzel D; Patti G; Renda G; Siller-Matula JM
    J Clin Med; 2020 Apr; 9(4):. PubMed ID: 32295160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI).
    Gibson CM; Mehran R; Bode C; Halperin J; Verheugt F; Wildgoose P; van Eickels M; Lip GY; Cohen M; Husted S; Peterson E; Fox K
    Am Heart J; 2015 Apr; 169(4):472-8.e5. PubMed ID: 25819853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticoagulation strategies in patients with atrial fibrillation after PCI or with ACS : The end of triple therapy?
    Fluschnik N; Becher PM; Schnabel R; Blankenberg S; Westermann D
    Herz; 2018 Feb; 43(1):20-25. PubMed ID: 29188358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triple Antithrombotic Therapy for Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.
    Kerneis M; Talib U; Nafee T; Daaboul Y; Pahlavani S; Pitliya A; Furqan MM; Datta S; Kazmi HA; Younes A; Gibson CM
    Prog Cardiovasc Dis; 2018; 60(4-5):524-530. PubMed ID: 29397950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease.
    Lopes RD; Rao M; Simon DN; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Go AS; Hylek EM; Kowey P; Piccini JP; Singer DE; Chang P; Peterson ED; Mahaffey KW
    Am J Med; 2016 Jun; 129(6):592-599.e1. PubMed ID: 26797080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is There a Role for Triple Therapy After ACS?
    Bhogal S; Alkhouli M; White CJ; Bailey S; Mamas M; Haddad E; Paul TK
    Curr Cardiol Rep; 2022 Mar; 24(3):191-200. PubMed ID: 35112242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights From the PIONEER AF-PCI Trial.
    Kerneis M; Gibson CM; Chi G; Mehran R; AlKhalfan F; Talib U; Pahlavani S; Mir M; Bode C; Halperin JL; Nafee T; Peterson ED; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Fox KAA; Cohen M
    JACC Cardiovasc Interv; 2018 Apr; 11(7):626-634. PubMed ID: 29550085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contemporary Antithrombotic Treatment in Patients with Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: Rationale and Design of the Greek AntiPlatElet Atrial Fibrillation (GRAPE-AF) Registry.
    Xanthopoulou I; Dragona VM; Davlouros P; Tsioufis C; Iliodromitis E; Alexopoulos D;
    Cardiovasc Drugs Ther; 2018 Apr; 32(2):191-196. PubMed ID: 29679301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antithrombotic treatment in patients with atrial fibrillation and acute coronary syndromes: results of the European Heart Rhythm Association survey.
    Lane DA; Dagres N; Dan GA; García Seara J; Iliodromitis K; Lenarczyk R; Lip GYH; Mansourati J; Marín F; Scherr D; Potpara TS
    Europace; 2019 Jul; 21(7):1116-1125. PubMed ID: 30874724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study.
    Lamberts M; Gislason GH; Lip GY; Lassen JF; Olesen JB; Mikkelsen AP; Sørensen R; Køber L; Torp-Pedersen C; Hansen ML
    Circulation; 2014 Apr; 129(15):1577-85. PubMed ID: 24470482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New oral anticoagulants and dual antiplatelet therapy: Focus on apixaban.
    Pelliccia F; Rollini F; Marazzi G; Greco C; Gaudio C; Angiolillo DJ; Rosano G
    Int J Cardiol; 2016 Dec; 225():154-158. PubMed ID: 27723533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.